UNITED THERAPEUTICS Corp
United Therapeutics develops and markets therapies for people with serious diseases with unmet medical needs, and researches technologies to expand the availability of transplantable organs. Its commercial portfolio includes Tyvaso DPI, Nebulized Tyvaso, Remodulin, Remunity and RemunityPRO Pumps, Orenitram, and Adcirca for pulmonary arterial hypertension; Tyvaso DPI and Nebulized Tyvaso also treat pulmonary hypertension associated with interstitial lung disease. Unituxin treats high-risk neuroblastoma. The company sells these products through specialty pharmaceutical distributors in the United States and pharmaceutical distributors internationally, and sells Nebulized Tyvaso, Remodulin, and Unituxin outside the United States. United Therapeutics also has products in development for pulmonary and other diseases, and researches organ technologies including xenotransplantation, regenerative medicine, and ex vivo lung perfusion. Its principal executive offices are in Silver Spring, Maryland, and Durham, North Carolina.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
ROTHBLATT MARTINE A (Chairperson & CEO) sold 9,500 indirectly-held shares of UNITED THERAPEUTICS Corp (UTHR) at an average of $594.78 ($590.43–$599.30, $5.65M total) across 9 trades on 2026-10-29 under a Rule 10b5-1 trading plan.
ROTHBLATT MARTINE A (Chairperson & CEO) sold 9,500 indirectly-held shares of UNITED THERAPEUTICS Corp (UTHR) at an average of $585.49 ($583.50–$588.39, $5.56M total) across 6 trades on 2026-10-28 under a Rule 10b5-1 trading plan.
ROTHBLATT MARTINE A (Chairperson & CEO) sold 9,500 indirectly-held shares of UNITED THERAPEUTICS Corp (UTHR) at an average of $587.73 ($582.66–$592.84, $5.58M total) across 11 trades on 2026-10-27 under a Rule 10b5-1 trading plan.
Over the past 7 days, AlphAI's AI scored 10 news stories mentioning UTHR (UNITED THERAPEUTICS Corp). Coverage has skewed bullish: 6 bullish, 3 neutral, and 1 bearish.
Recent UTHR coverage spans insider activity, financial news and regulation.
In the last 30 days, UTHR insiders filed 307 SEC Form 4 transactions — no purchases and 307 sales ($120.7M). The most active reporter was ROTHBLATT MARTINE A, Chairperson & CEO, with 291 filings. 100% of those filings were made under pre-arranged Rule 10b5-1 plans.
Insider sale may signal confidence concerns, potentially pressuring the stock.
The insider sale may signal modest downside pressure on United Therapeutics.
Insider sale may signal modest downside pressure.
The clearance removes a regulatory hurdle, potentially boosting United Therapeutics' pipeline valuation.
The insider sale represents a modest reduction of the CEO's stake and may signal short‑term selling pressure.
AlphAI scores every news story that mentions UTHR with an AI model for sentiment and relevance, and aggregates insider trades from UNITED THERAPEUTICS Corp's SEC EDGAR Form 4 filings. Figures refresh continuously.
ROTHBLATT MARTINE A (Chairperson & CEO) sold 9,500 indirectly-held shares of UNITED THERAPEUTICS Corp (UTHR) at an average of $594.78 ($590.43–$599.30, $5.65M total) across 9 trades on 2026-10-29 under a Rule 10b5-1 trading plan.
1 min readROTHBLATT MARTINE A (Chairperson & CEO) sold 9,500 indirectly-held shares of UNITED THERAPEUTICS Corp (UTHR) at an average of $585.49 ($583.50–$588.39, $5.56M total) across 6 trades on 2026-10-28 under a Rule 10b5-1 trading plan.
1 min readROTHBLATT MARTINE A (Chairperson & CEO) sold 9,500 indirectly-held shares of UNITED THERAPEUTICS Corp (UTHR) at an average of $587.73 ($582.66–$592.84, $5.58M total) across 11 trades on 2026-10-27 under a Rule 10b5-1 trading plan.
1 min readThe FDA approved a trial for Treprostinil-Iloprost SMI, a potential first as-needed inhaler therapy for pulmonary arterial hypertension (PAH). United Therapeutics plans a phase 1 study in 2026, with a phase 2 study in PAH patients anticipated in 2027. The therapy combines treprostinil and iloprost, aiming to provide episodic symptom relief. United Therapeutics aims to expand its PAH treatment portfolio.
2 min readROTHBLATT MARTINE A (Chairperson & CEO) sold 9,500 indirectly-held shares of UNITED THERAPEUTICS Corp (UTHR) at an average of $588.64 ($585.71–$592.92, $5.59M total) across 8 trades on 2026-10-26 under a Rule 10b5-1 trading plan.
1 min readGroup 1 Automotive (GPI) saw a $24.2M insider purchase by Conifer Management, while Corebridge Financial (CRBG) had an $8.7M buy by Nippon Life. Optimum Communications (OPTU) and Korro Bio (KRRO) also reported insider buys. Gentherm (THRM) had a $532.6K purchase. On the sell side, Intuitive Surgical (ISRG), Charles River Labs (CRL), Lam Research (LRCX), United Therapeutics (UTHR), and PACS Group (PACS) reported insider sales.
2 min readAn insider of United Therapeutics sold shares worth $5,536,235, as disclosed in a recent SEC filing. The company's stock is currently trading at $592.84, with a 5-day change of +0.91%, a 1st Jan change of +9.15%, and a year-to-date change of +21.67%.
1 min readROTHBLATT MARTINE A (Chairperson & CEO) sold 9,500 indirectly-held shares of UNITED THERAPEUTICS Corp (UTHR) at an average of $582.76 ($577.68–$588.00, $5.54M total) across 11 trades on 2026-10-23 under a Rule 10b5-1 trading plan.
1 min readUnited Therapeutics (UTHR) CEO Martine Rothblatt sold $5.5M of shares on Oct. 22, part of a $80M+ monthly selling spree under a 10b5-1 plan. Shares rose 3.8% to $584.79, near a 52-week high. Q2 revenue fell 2% to $783.3M, but net income rose 8% to $333M. The company is awaiting regulatory decisions on new drugs and developing pig organs for transplants.
2 min readROTHBLATT MARTINE A (Chairperson & CEO) sold 9,500 indirectly-held shares of UNITED THERAPEUTICS Corp (UTHR) at an average of $583.38 ($562.97–$590.40, $5.54M total) across 21 trades on 2026-10-22 under a Rule 10b5-1 trading plan.
1 min read
